Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

People In The News: Tracking The Latest Industry Personnel Moves

  • News

Executive Summary

Presidents And CEOs

You may also be interested in...



Merck's Frazier Promoted to CEO to Steer Merck To Post-Schering Success

In a widely anticipated move, Merck has named current president Ken Frazier as CEO

Lilly Acquires ICOS To Bring Full Value Of Cialis In House

$2.1 bil. deal will allow Lilly to benefit from efficiencies in development, marketing and sales of the erectile dysfunction product.

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest News

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

OIG Accelerated Approval Report Spotlights Financial Costs Ahead Of Congressional Debate

Amylyx's Relyvrio: The Road To Regulatory Flexibility And US FDA Approval

Regulatory Flexibility: US FDA Approves Amylyx’s Relyvrio For ALS Despite ‘Degree Of Residual Uncertainty’

See All
UsernamePublicRestriction

Register

PS052914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By